Pharma BD Deal Intelligence
Ventana became the durable backbone of Roche's companion-diagnostics franchise — 17+ years on, still branding the assays that gate access to Roche's own blockbuster oncology drugs.
Full analysis, sources & comparables →Roche commenced a tender offer to acquire all outstanding common shares of Ventana for $75.00 per share in cash, representing a 44% premium to Ventana's June…
After a six-month hostile process — Ventana had called the original $75 bid 'grossly inadequate' — Roche raised to $89.50/share and won the board's…
Roche held about 70.5% of Ventana shares following expiration of the tender offer at $89.50 per share, and began a subsequent offering period to acquire the…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Initial $75/share hostile bid June 2007 ($3B); raised to $89.50/share ($3.4B) Jan 2008 to close. Tissue diagnostics. Source: Dark Daily, CNBC, C&EN.
Ventana became the durable backbone of Roche's companion-diagnostics franchise — 17+ years on, still branding the assays that gate access to Roche's own blockbuster oncology drugs.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Ventana Medical Systems Inc. (this deal) | 2007 | $3.4B | 88 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2007 deals · Roche Holding AG deals